Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.
Background: Qualitative interviews can supplement clinical trial results by providing in-depth insights into participant experiences. In the recent SURMOUNT-OSA (NCT05412004) phase III trials, tirzepatide demonstrated favorable efficacy and safety in patients with moderate-to-severe obstructive slee...
| Publicado en: | Patient Vol. 19; no. 4; pp. 601 - 615 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194750402&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194750402 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11781653 91S4 jtl: Patient issn: 11781653 maglogo: N pubinfo: dt: Jul2026 vid: 19 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 194750402 192142005 194750402 194750402 10.1007/s40271-026-00808-3 194750402 ppf: 601 ppct: 14 formats: tig: atl: Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study. aug: au: Shinde, Shraddha Kanu, Chisom Varnado, Oralee J. Bednarik, Jo Dennehy, Ellen B. Dias-Barbosa, Carla Taylor, Natalie affil: https://ror.org/01qat3289 Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., 46285, Indianapolis, IN, USA sug: subj: Sleep Apnea, Obstructive Psychosocial Factors Sleep Apnea, Obstructive Drug Therapy Glucagon-Like Peptide-1 Receptor Agonists Therapeutic Use Patient Attitudes Evaluation Attitude to Illness Evaluation Attitude to Medical Treatment Evaluation Sleep Apnea, Obstructive Epidemiology Sleep Apnea, Obstructive Epidemiology Research Subjects Psychosocial Factors Randomized Controlled Trials Human Male Female Cross Sectional Studies Multimethod Studies Thematic Analysis Interviews Adult Middle Age Aged Funding Source Sleep Quality Patient Satisfaction Data Analysis Software Descriptive Statistics United States Germany Placebos Administration and Dosage Snoring Sleep Deprivation Drug Efficacy Functional Status Glucagon-Like Peptide-1 Receptor Agonists Administration and Dosage Weight Control Multicenter Studies Interview Guides Pretest-Posttest Control Group Design Clinical Assessment Tools Polysomnography Patient-Reported Outcomes Summated Rating Scaling Sleep Apnea, Obstructive Symptoms Urination Disorders Xerostomia Affect Work Schools Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Male Female ab: Background: Qualitative interviews can supplement clinical trial results by providing in-depth insights into participant experiences. In the recent SURMOUNT-OSA (NCT05412004) phase III trials, tirzepatide demonstrated favorable efficacy and safety in patients with moderate-to-severe obstructive sleep apnea and obesity. To explore participants' obstructive sleep apnea and treatment-related experiences, qualitative exit interviews were held with a subset of trial participants. Methods: One-on-one qualitative telephone interviews were conducted as participants exited the trial. Participants described their obstructive sleep apnea symptoms, impacts, and sleep quality before and after participation in the trial. They further reported on the meaningfulness of treatment-related changes, experiences, and satisfaction. Interview transcripts were analyzed using ATLAS.ti. Results: Seventy US-based and 12 Germany-based participants (tirzepatide n = 49, placebo n = 33) had a mean age of 52.7 years. Most were male (61.0%), non-Hispanic (87.8%), and White (91.5%). The "worst" obstructive sleep apnea symptoms experienced overall included snoring and temporary breath cessation, and the "worst" impacts were sleep-related impairment and sleep disturbance. Greater proportions of tirzepatide-treated than placebo-treated patients reported improvements in key symptoms and impacts of obstructive sleep apnea and considered them to be meaningful. Tirzepatide-treated participants also reported improved sleep quality and daytime functioning. Treatment satisfaction was higher among tirzepatide-treated participants than placebo-treated participants. The most common treatment-related likes were ease of treatment administration, weight reduction, and obstructive sleep apnea symptom improvement. Conclusions: These findings highlight the range of symptoms and impacts experienced by individuals with obstructive sleep apnea and obesity, and support a positive effect of treatment with tirzepatide. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|